Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

Clinical Biochemistry

Volumn 51, Issue , 2018, Pages 66-71

  Murata, Kazunori ^a   McCash, Samuel I ^a   Carroll, Brittany ^a   Lesokhin, Alexander M ^a   Hassoun, Hani ^a   Lendvai, Nikoletta ^a   Korde, Neha S ^a   Mailankody, Sham ^a   Landau, Heather J ^a   Koehne, Guenther ^a   Chung, David J ^a   Giralt, Sergio A ^a   Ramanathan, Lakshmi V ^a   Landgren, Ola ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Daratumumab; Electrophoresis; Elotuzumab; Immunofixation; Isatuximab; Myeloma

Indexed keywords

DARATUMUMAB; ELOTUZUMAB; ISATUXIMAB; M PROTEIN; MONOCLONAL ANTIBODY; MULTIPLE MYELOMA M-PROTEINS; PARAPROTEIN;

ARTICLE; CANCER PATIENT; DRUG BLOOD LEVEL; HEAVY CHAIN; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; MALE; MAXIMUM CONCENTRATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; BLOOD; CASE CONTROL STUDY; FALSE POSITIVE RESULT; METABOLISM; PROCEDURES;

ANTIBODIES, MONOCLONAL; BLOOD PROTEIN ELECTROPHORESIS; CASE-CONTROL STUDIES; FALSE POSITIVE REACTIONS; HUMANS; MALE; MULTIPLE MYELOMA; MYELOMA PROTEINS;

EID: 84995768430     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.09.015     Document Type: Article

References (17)

1. McCudden, C.R., Voorhees, P.M., Hainsworth, S.A., Whinna, H.C., Chapman, J.F., Hammett-Stabler, C.A., et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin. Chem. 56 (2010), 1897–1899.
2. Deckert, J., Wetzel, M.C., Bartle, L.M., Skaletskaya, A., Goldmacher, V.S., Vallee, F., et al. Sar650984, a novel humanized cd38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other cd38 + hematologic malignancies. Clin. Cancer Res. 20 (2014), 4574–4583.
3. Lonial, S., Kaufman, J., Laubach, J., Richardson, P., Elotuzumab: a novel anti-cs1 monoclonal antibody for the treatment of multiple myeloma. Expert. Opin. Biol. Ther. 13 (2013), 1731–1740.
4. Nijhof, I.S., Groen, R.W., Lokhorst, H.M., van Kessel, B., Bloem, A.C., van Velzen, J., et al. Upregulation of cd38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia, 2015.
5. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006), 1467–1473.
6. Zonder, J.A., Mohrbacher, A.F., Singhal, S., van Rhee, F., Bensinger, W.I., Ding, H., et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120 (2012), 552–559.
7. Durie, B.G., Miguel, J.F., Blade, J., Rajkumar, S.V., Clarification on the definition of complete response in multiple myeloma. Leukemia, 2015.
8. Inman, Z., Martin, H., Chubb, S.A., Reporting of quantitative protein electrophoresis in Australia and New Zealand: a call for standardisation. Clin. Biochem. Rev. 30 (2009), 141–151.
9. Axel, A.E., McCudden, C.R., Xie, H., Hall, B.M., Sasser, A.K., Development of clinical assay to mitigate daratumumab, an igg1 kappa monoclonal antibody, interference with serum immunofixation (ife) and clinical assessment of m-protein response in multiple myeloma. Cancer Res., 74, 2014.
10. McCudden, C., Axel, A., Slaets, D., Frans, S., Bald, J., Schecter, J.M., et al. Assessing clinical response in multiple myeloma (mm) patients treated with monoclonal antibodies (mabs): validation of a daratumumab ife reflex assay (dira) to distinguish malignant m-protein from therapeutic antibody. J. Clin. Oncol., 33, 2015.
11. Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., et al. Targeting cd38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373 (2015), 1207–1219.
12. van de Donk, N.W., Otten, H.G., El Haddad, O., Axel, A., Sasser, A.K., Croockewit, S., et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab ife reflex assay (dira). Clin. Chem. Lab. Med., 2016.
13. Barnidge, D.R., Dasari, S., Botz, C.M., Murray, D.H., Snyder, M.R., Katzmann, J.A., et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J. Proteome Res. 13 (2014), 1419–1427.
14. Barnidge, D.R., Tschumper, R.C., Theis, J.D., Snyder, M.R., Jelinek, D.F., Katzmann, J.A., et al. Monitoring m-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and lc-ms/ms. J. Proteome Res. 13 (2014), 1905–1910.
15. Mills, J.R., Barnidge, D.R., Murray, D.L., Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 81 (2015), 56–65.
16. Willrich, M.A., Ladwig, P.M., Andreguetto, B.D., Barnidge, D.R., Murray, D.L., Katzmann, J.A., et al. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin. Chem. Lab. Med. 54 (2016), 1085–1093.
17. Ruinemans-Koerts, J., Verkroost, C., Schmidt-Hieltjes, Y., Wiegers, C., Curvers, J., Thelen, M., et al. Interference of therapeutic monoclonal immunoglobulins in the investigation of m-proteins. Clin. Chem. Lab. Med. 52 (2014), e235–e237.